NCT07144345 2026-03-05
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
Sun Pharmaceutical Industries Limited
Phase 3 Active not recruiting
Clinical Trials
14 trialsNCT07144852 2026-02-20
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
Sun Pharmaceutical Industries Limited
Phase 3 Active not recruiting
NCT06135415 2026-01-22
TirbAKare
Almirall, S.A.
Phase 3 Completed
NCT05060237 2024-10-17
Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
Biofrontera Bioscience GmbH
Phase 1 Completed
NCT02844777 2023-01-12
Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis
Vidac Pharma
Phase 2 Completed
NCT03285477 2021-04-13
AK003
Almirall, S.A.
Phase 3 Completed
NCT00103246 2019-01-22
Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00021294 2018-09-11
Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis
University of Arizona
Phase 2 Completed
NCT00524485 2017-06-14
Photodynamic Therapy Using Topical Aminolevulinic Acid in Treating Patients With Actinic Keratosis
Roswell Park Cancer Institute
Phase NA Terminated
NCT00608634 2015-04-01
Topical Perillyl Alcohol in Treating Patients With Sun Damaged Skin and Actinic Keratoses
University of Arizona
Phase 2 Completed
NCT00002811 2013-11-06
T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00002975 2013-10-10
Photodynamic Therapy in Treating Patients With Skin Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT00027976 2013-08-05
Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses
University of Alabama at Birmingham
Phase 2/3 Withdrawn
NCT00175643 2006-05-09
Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses
University of British Columbia
Phase 3 Completed